Abbott Laboratories $ABT raised its full-year earnings outlook, powered by booming medical device sales and strong profit margin expansion. THE NUMBERS: Operational execution was stellar, driving adjusted gross margin to 58% and bumping full-year EPS guidance up to a $5.45–$5.60 range. THE MOMENTUM: Management expects the acceleration to carry into H2, forecasting Q3 earnings of up to $1.46 per share. THE BALANCE: While core medical devices are flying, a sharp decline in respiratory testing revenue keeps the Seeking Alpha Quant rating locked at a neutral HOLD. Are you buying $ABT for its high-margin medical tech pipeline, or is the dropping diagnostics segment a warning sign?
Seeking AlphaShare
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.